Visualize how your peptide clears from the body — half-life, steady state, and accumulation for every injection schedule.
Half-Life
~5 days
Time for 50 % to be eliminated
Steady State
~21.6 days
≈ 4.3 half-lives
Accumulation
×1.61
Cmax at steady state ÷ Cmax first dose
Gone After
~35 days
after last dose
| Hour | % of peak |
|---|---|
| 0 | 100 |
| 100.8 | 55.9 |
| 201.6 | 113.6 |
| 302.4 | 63.4 |
| 403.2 | 103.3 |
| 504 | 157.7 |
| 604.8 | 88.1 |
| 705.6 | 131.6 |
| 806.4 | 73.5 |
| 907.2 | 108.9 |
| 1008 | 160.8 |
| 1108.8 | 89.8 |
| 1209.6 | 132.6 |
| 1310.4 | 74 |
| 1411.2 | 41.4 |
| 1512 | 23.1 |
| 1612.8 | 12.9 |
| 1713.6 | 7.2 |
| 1814.4 | 4 |
| 1915.2 | 2.3 |
Source: Eli Lilly SURPASS-1 clinical trial. Research tool. Uses a simplified first-order elimination model and normalizes concentration to % of peak. Not a medical or dosing recommendation. Tirzepatide: ~5 days.
Tirzepatide has a reported half-life of about 5 days. Under a weekly dosing schedule, steady state is reached at roughly 4.3 half-lives — about 22 days — and subsequent doses accumulate by a factor of about 1.6 over a single dose.
The blue line plots concentration as a percentage of the first-dose peak. The dashed reference line marks the steady-state peak. After the last dose, concentration drops below 1 % of the peak after about 35 days — seven half-lives.
Tirzepatide is a dual GLP-1/GIP receptor agonist studied at weekly doses of 2.5 to 15 mg. Its 5-day half-life is shorter than semaglutide, resulting in slightly less accumulation and a faster approach to steady state under the same weekly interval.